Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.19
(-1.85%)
SEK 0.19
(-1.85%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 482.17 Million SEK | 81.52% |
| 2022 | 265.62 Million SEK | 3.48% |
| 2021 | 256.68 Million SEK | 24.57% |
| 2020 | 206.05 Million SEK | 33.27% |
| 2019 | 154.61 Million SEK | -8.95% |
| 2018 | 169.81 Million SEK | 652.89% |
| 2017 | 22.55 Million SEK | 108.67% |
| 2016 | 10.8 Million SEK | -61.15% |
| 2015 | 27.82 Million SEK | 7020.88% |
| 2014 | 390.7 Thousand SEK | -22.7% |
| 2013 | 505.43 Thousand SEK | -11.15% |
| 2012 | 568.89 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 579.51 Million SEK | 8.8% |
| 2024 Q2 | 532.64 Million SEK | 5.57% |
| 2024 Q1 | 504.53 Million SEK | 4.64% |
| 2023 Q4 | 482.17 Million SEK | -13.83% |
| 2023 Q1 | 283.51 Million SEK | 6.73% |
| 2023 FY | 482.17 Million SEK | 81.52% |
| 2023 Q3 | 559.56 Million SEK | -6.54% |
| 2023 Q2 | 598.72 Million SEK | 111.18% |
| 2022 FY | 265.62 Million SEK | 3.48% |
| 2022 Q3 | 255.69 Million SEK | -19.58% |
| 2022 Q2 | 317.96 Million SEK | 13.77% |
| 2022 Q1 | 279.48 Million SEK | 8.88% |
| 2022 Q4 | 265.62 Million SEK | 3.88% |
| 2021 Q1 | 265.38 Million SEK | 28.79% |
| 2021 FY | 256.68 Million SEK | 24.57% |
| 2021 Q4 | 256.68 Million SEK | 9.43% |
| 2021 Q3 | 234.56 Million SEK | 0.21% |
| 2021 Q2 | 234.06 Million SEK | -11.8% |
| 2020 Q1 | 171.85 Million SEK | 11.15% |
| 2020 Q4 | 206.05 Million SEK | 13.78% |
| 2020 Q3 | 181.1 Million SEK | -26.43% |
| 2020 FY | 206.05 Million SEK | 33.27% |
| 2020 Q2 | 246.17 Million SEK | 43.25% |
| 2019 Q2 | 167.49 Million SEK | -13.24% |
| 2019 Q1 | 193.04 Million SEK | 13.68% |
| 2019 FY | 154.61 Million SEK | -8.95% |
| 2019 Q4 | 154.61 Million SEK | -6.12% |
| 2019 Q3 | 164.69 Million SEK | -1.68% |
| 2018 Q1 | 46.5 Million SEK | 106.17% |
| 2018 FY | 169.81 Million SEK | 652.89% |
| 2018 Q4 | 169.81 Million SEK | 5.74% |
| 2018 Q3 | 160.59 Million SEK | 126.37% |
| 2018 Q2 | 70.94 Million SEK | 52.57% |
| 2017 Q1 | 14.33 Million SEK | 32.64% |
| 2017 Q2 | 13.89 Million SEK | -3.08% |
| 2017 Q3 | 12.01 Million SEK | -13.5% |
| 2017 Q4 | 22.55 Million SEK | 87.66% |
| 2017 FY | 22.55 Million SEK | 108.67% |
| 2016 Q2 | 13.99 Million SEK | -22.78% |
| 2016 Q3 | 13.11 Million SEK | -6.29% |
| 2016 Q4 | 10.8 Million SEK | -17.59% |
| 2016 FY | 10.8 Million SEK | -61.15% |
| 2016 Q1 | 18.12 Million SEK | -34.86% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q3 | 20.5 Million SEK | 0.0% |
| 2015 Q4 | 27.82 Million SEK | 35.71% |
| 2015 FY | 27.82 Million SEK | 7020.88% |
| 2014 FY | 390.7 Thousand SEK | -22.7% |
| 2014 Q4 | 390.7 Thousand SEK | 0.0% |
| 2013 FY | 505.43 Thousand SEK | -11.15% |
| 2012 FY | 568.89 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Active Biotech AB (publ) | 13.4 Million SEK | -3498.306% |
| Biovica International AB (publ) | 34.76 Million SEK | -1286.87% |
| Cantargia AB (publ) | 54.97 Million SEK | -777.157% |
| CombiGene AB (publ) | 4.15 Million SEK | -11501.856% |
| Cyxone AB (publ) | 4.69 Million SEK | -10172.113% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -6541.501% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -3401.219% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -3517.745% |
| Fluicell AB (publ) | 8.91 Million SEK | -5308.559% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -944.117% |
| Mendus AB (publ) | 51.22 Million SEK | -841.285% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -2416.035% |
| I-Tech AB | 16.2 Million SEK | -2875.458% |
| Intervacc AB (publ) | 21.68 Million SEK | -2124.045% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -9248.061% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | -288.915% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -20339.72% |
| OncoZenge AB (publ) | 1.69 Million SEK | -28279.812% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -1293.443% |
| Lipum AB (publ) | 7.53 Million SEK | -6296.564% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | -352.341% |
| Ziccum AB (publ) | 6.38 Million SEK | -7448.106% |
| BioArctic AB (publ) | 139.5 Million SEK | -245.636% |
| Genovis AB (publ.) | 98.04 Million SEK | -391.777% |
| Camurus AB (publ) | 414.81 Million SEK | -16.237% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -685.848% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -2891.704% |
| Aptahem AB (publ) | 8.99 Million SEK | -5258.772% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -1080.09% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -571.083% |
| Kancera AB (publ) | 17.97 Million SEK | -2582.017% |
| Saniona AB (publ) | 86.08 Million SEK | -460.126% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -4032.439% |
| AcouSort AB (publ) | 10.37 Million SEK | -4546.107% |
| Xintela AB (publ) | 14.01 Million SEK | -3340.407% |
| Abliva AB (publ) | 16.78 Million SEK | -2773.327% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -4067.802% |
| Amniotics AB (publ) | 10.54 Million SEK | -4471.66% |
| 2cureX AB (publ) | 2.93 Million SEK | -16328.382% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -10794.103% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 69.205% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 59.342% |
| Biosergen AB | 5.08 Million SEK | -9382.262% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -1705.35% |
| Corline Biomedical AB | 6.78 Million SEK | -7002.268% |
| NextCell Pharma AB | 13.68 Million SEK | -3422.325% |
| Nanologica AB (publ) | 79.32 Million SEK | -507.83% |
| LIDDS AB (publ) | 3.75 Million SEK | -12737.407% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | -124.685% |
| BioInvent International AB (publ) | 90.45 Million SEK | -433.065% |
| SynAct Pharma AB | 51.83 Million SEK | -830.225% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -5965.832% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -9181.584% |
| Alzinova AB (publ) | 9.33 Million SEK | -5067.431% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -3683.53% |
| Oncopeptides AB (publ) | 181.59 Million SEK | -165.517% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -26776.979% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -2507.186% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -12463.132% |
| Simris Alg AB (publ) | 148.93 Million SEK | -223.741% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -577.99% |